Georgia's Online Cancer Information Center

Find A Treatment Site

Winship Cancer Institute of Emory University

Winship Cancer Institute NCI Designated Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Winship Cancer Institute of Emory University is Georgia's first and only comprehensive cancer center designated by the National Cancer Institute (NCI). Designation requires meeting rigorous criteria for the depth and breadth of basic science and clinical research, in addition to cancer prevention, control, and population/behavioral sciences. It requires effective collaboration among various disciplines and with community partners in private practice and in academic centers throughout Georgia and across the nation. With this recognition comes the responsibility to provide public information, education and outreach to other health care professionals and the community. NCI designation for Winship gives Georgians improved access to clinical trials and resources that may not be available elsewhere.

The Winship Cancer Institute (Winship) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Winship is dedicated to the integration of innovative clinical and basic science research with outstanding patient care for the prevention, treatment and control of cancer.

1-888-946-7447
winshipcancer.emory.edu

Treatment Sites in Georgia

Primary Location

1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-1900 (p)
winshipcancer.emory.edu

driving directions

Doctors

Abeer N. AbouYabis MD
Nazmi Volkan Adsay MD
Michael R. Aho MD
Mehmet Akce MD
Mehrdad Alemozaffar MD
Olatunji B. Alese MD
Olatunji B. Alese MD
Pamela Blair Allen MD, MSc
Ana Antun MD
Jack Arbiser MD, PhD
Cletus A. Arciero MD
Martha L. Arellano MD
Bruce J. Barron MD
Deborah A. Baumgarten MD, MPH
Jonathan J. Beitler MD, MBA, FACR
Leon Bernal MD
George G. A. Birdsong MD
William G. Blum
Daniel J. Brat MD, PhD
Otis W. Brawley MD
Joan Cain MD, MSc
Grant W. Carlson MD
Bradley C. Carthon, MD, PhD
Amy Y. Chen MD
Cynthia Cohen MD
Jonathon B Cohen MD, MS
Michael A. Cohen MD, FACR
Laronna S Colbert MD
Ian R. Crocker MD, FACR
Walter J Curran, Jr. MD, FACR
Keith A. Delman MD, FACS
Maria Diab MD
Roberto R. Diaz MD
Scott H. Edelman MD
John William Eley MD, MPH
Bassel F El-Rayes MD
Tony Y Eng MD
Christopher R. Flowers MD
Sarah Friend MD
Sheryl A. Gabram-Mendola MD, MBA, FACS
Manila Gaddh , MD
Anthony Andrew Gal MD
Jacques Galipeau MD
Karen D. Godette MD
Keerthi Gogineni MD
Bruce D Goldsweig MD
Cathy L Graham MD, FACS
William J. Grist MD
Kathleen Gundry MD
Vikas A Gupta MD
Raghuveer K. Halkar MD
Chunhai Hao MD, PhD
Wayne B. Harris MD
R. Donald Harvey , PharmD
Natalyn N. Hawk MD
Leonard T. Heffner Jr., MD
Bruce W. Hershatter MD
Kristin Higgins MD
Charles E. Hill MD
Craig C Hofmeister MD, MPH
Chad A. Holder MD
Stephen B. Hunter MD
Sol Jacobs MD
Ashesh B. Jani MD
David L. Jaye MD
Jade Jones MD
Jonathan L. Kaufman MD
H. Jean Khoury MD, FACP
Kevin Kim MD
Adam M. Klein MD
Rebecca Bruner Klisovic MD
Jean L Koff MD
David A. Kooby MD
Vamsi K. Kota MD
Joan Kramer
Omer Kucuk MD
Ragini R Kudchadkar MD
J. David Lambeth MD, PhD
Jerome C. Landry MD
Amelia A. Langston MD
Stephen K. Lau MD
David H. Lawson MD
Mary Jo Lechowicz MD
Daniel J. Lee MD
Melinda Moore Lewis MD
Shiyong Li MD, PhD
Jolinta Y Lin MD
James V. Little MD
Sagar Lonial MD
Shishir K. Maithel MD
Anant Mandawat MD
Karen P. Mann MD, PhD
Viraj Master MD, PhD
Mark William McDonald MD
Morgan L. McLemore MD
Jane L Meisel MD
Daniel L. Miller MD
Leon Bernal- Mizrachi MD
David K Monson MD
Melvin Moore MD
Mario Mosunjac MD
Susan C. Muller DMD, MS
Padma C. Nadella MD
Mary S. Newell MD
Peter T. Nieh MD
Ajay K. Nooka MD, MPH
William O'Connell MD
Kenneth Ogan MD
Joel A Okoli MD MPH
Jeffrey J. Olson MD
Gabriela M. Oprea MD
Adeboye O. Osunkoya MD, FCAP
Taofeek K. Owonikoko MD
Nelson M. Oyesiku MD, PhD, FACS
Nicki Panoskaltsis MD, PhD, FRCP
Nicki Panoskaltsis MD, PhD, FRCP
Elisavet Paplomata MD
Douglas C. Parker MD
Pretesh Patel MD
Sagar A Patel MD
Allan Pickens MD
Rathi Pillai MD
Brian P Pollack MD, PhD
Suresh S. Ramalingam MD
William Read , MD
Satyanarayan K. Reddy MD
Nickolas B Reimer MD
Maria J. Ribeiro MD
Chad W Ritenour MD
Monica Rizzo MD
Steven M. Roser DMD, MD
Peter J. Rossi MD
Nabil F. Saba MD, FACP
Ruth Sacks MD
Manu S Sancheti
Martin G Sanda MD
Juan M. Sarmiento MD
Neil D Saunders MD
David M. Schuster MD
Judy H. Sequeira MD
Charles W. Sewell MD
Virginia O Shaffer MD
Mihir M Shah MD
Jyotirmay Sharma MD
Dong Moon Shin MD
Hui-Kuo G. Shu MD, PhD
Mark Shumate MD, MPH
Gabriel L. Sica MD
Momin T. Siddiqui MD, FIAC
William C. Small MD
Cyril O. Spann MD,SM, FACOG, FACS
Charles A. Staley MD
Liza J. Stapleford MD
Sidney F. Stein MD
Conor F Steuer
Toncred M. Styblo MD
Preeti D Subhedar MD, MSPT
Pakkala Suchita
Ajay Tadepalli MD
Talaat S. Tadros MD
Ahmad Tarhini MD, PhD
Meena Thirunavu MD
Mylin A. Torres MD
William E. Torres MD
Keriann M. Van Nostrand MD
Vijay Alluri Varma MD
Alfredo D. Voloschin MD
J. Trad Wadsworth MD
Edmund K. Waller MD, PhD, FACP
Mark D Walsh MD, FACS
Carl Washington MD
Sharon W. Weiss MD
Ifor R. Williams MD, PhD
Elliott F. Winton MD
Christina Wu MD
Howa Yeung MD
David Yu MD
Melinda L Yushak
Jim Zhong MD

Clinical Trials in Georgia

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type: Hematopoietic Malignancies, Leukemia, Unknown Primary

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

9-ING-41 in Patients With Advanced Cancers
Cancer Type: Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma

A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Cancer Type: Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer

A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Cancer Type: Colon/Rectal Cancer, Lung Cancer

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type: Hematopoietic Malignancies
Study Coordinator: Heather Renfroe - 404-778-5127


A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cancer Type: Colon/Rectal Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer

A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Cancer Type: Solid Tumor, Unknown Primary

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)
Cancer Type: Lung Cancer

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type: Hematopoietic Malignancies, Solid Tumor

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type: Leukemia, Non-Hodgkin Lymphoma

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type: Prostate Cancer , Unknown Primary

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Cancer Type: Solid Tumor, Unknown Primary

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which has Spread to the Lymph Nodes (The INSPIRE Study)
Cancer Type: Bladder Cancer

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Cancer Type: Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type: Unknown Primary

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Cancer Type: Solid Tumor, Unknown Primary

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Cancer Type: Breast Cancer, Solid Tumor, Unknown Primary

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Cancer Type: Leukemia, Lymphoma, Non-Hodgkin Lymphoma

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Cancer Type: Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type: Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type: Leukemia

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Cancer Type: Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type: Colon/Rectal Cancer, Lung Cancer, Melanoma

A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Cancer Type: Cervical Cancer

A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type: Germ Cell Tumor

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Cancer Type: Multiple Myeloma

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type: Sarcoma

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type: Bile Duct Cancer

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type: Hematopoietic Malignancies, Solid Tumor

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type: Pancreatic Cancer

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Biopsy of Breast after Chemotherapy in Predicting Pathologic Response in Patients with Breast Cancer Undergoing Breast Conserving Surgery
Cancer Type: Breast Cancer

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Cancer Type: Leukemia

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Brentuximab Vedotin and Nivolumab in Treating Patients with Early Stage Classic Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type: Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary

Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer
Cancer Type: Unknown Primary

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with High-Risk Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

CAR-T Long Term Follow Up (LTFU) Study
Cancer Type: Unknown Primary

Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Cancer Type: Head and Neck Cancer, Unknown Primary

Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type: Hodgkin Lymphoma, Leukemia, Lymphoma

Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer
Cancer Type: Prostate Cancer , Unknown Primary

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer

Daratumumab, Ixazomib, and Dexamethasone with or without Bortezomib in Treating Patients with Newly Diagnosed Multiple Myeloma
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Therapy
Cancer Type: Lung Cancer

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Cancer Type: Breast Cancer, Cervical Cancer, Esophogeal Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Lung Cancer, Lymphoma, Stomach/ Gastric Cancer

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Cancer Type: Solid Tumor

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type: Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma

Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type: Breast Cancer, Unknown Primary

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type: Hematopoietic Malignancies

First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Cancer Type: Lung Cancer

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type: Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Primary Peritoneal Cancer

First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer

First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)
Cancer Type: Leukemia

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Cancer Type: Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor

Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type: Prostate Cancer , Unknown Primary

Gemcitabine and Cisplatin with Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Cancer Type: Bile Duct Cancer

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Cancer Type: Lung Cancer

GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Cancer Type: Cervical Cancer, Lung Cancer

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type: Hematopoietic Malignancies, Multiple Myeloma

Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Cancer Type: Leukemia, Lymphoma, Non-Hodgkin Lymphoma

Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study
Cancer Type: Brain & Spinal Cord Tumor

ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer
Cancer Type: Penile Cancer

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Cancer Type: Hodgkin Lymphoma

Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Cancer Type: Head and Neck Cancer, Unknown Primary

Inducing a Hypothyroxinemic State in Patients with Recurrent Glioblastoma or Gliosarcoma
Cancer Type: Brain & Spinal Cord Tumor

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type: Leukemia

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type: Prostate Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Cancer Type: Breast Cancer

Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type: Lung Cancer

KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type: Colon/Rectal Cancer, Eye Cancer, Melanoma, Mesothelioma, Prostate Cancer , Solid Tumor, Unknown Primary

Letrozole with and without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type: Breast Cancer

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients with Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Cancer Type: Colon/Rectal Cancer

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type: Bone Tumor, Multiple Myeloma, Plasma cell neoplasm

Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Cancer Type: Neuroblastoma, Neurologocal Tumor, Sarcoma

NFKB2 Rearrangement in Guiding Treatment with Ixazomib Citrate and Dexamethasone or Ixazomib Citrate, Dexamethasone and Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Nivolumab and Degarelix with or without BMS-986253 in Treating Patients with Hormone-Sensitive Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors
Cancer Type: Adrenal Cancer, Bladder Cancer, Neuroendocrine Tumor, Penile Cancer, Prostate Cancer , Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer

Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type: Hematopoietic Malignancies

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type: Brain & Spinal Cord Tumor

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations
Cancer Type: Bile Duct Cancer, Brain & Spinal Cord Tumor

Opaganib and Androgen Antagonists for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Palbociclib with Cisplatin or Carboplatin in Treating Patients with Advanced Solid Tumors
Cancer Type: Breast Cancer, Lung Cancer, Pancreatic Cancer, Solid Tumor, Unknown Primary

Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Cancer Type: Lung Cancer

Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Pembrolizumab with and without Intra-operative Radiation Therapy in Treating Patients with Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Cancer Type: Stomach/ Gastric Cancer

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Cancer Type: Lung Cancer, Prostate Cancer

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type: Head and Neck Cancer, Sarcoma, Solid Tumor

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type: Colon/Rectal Cancer, Pancreatic Cancer, Sarcoma, Solid Tumor

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Cancer Type: Breast Cancer, Unknown Primary

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Proof-of-concept Trial of Apraglutide in GVHD
Cancer Type: Unknown Primary

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients with IDH Mutant Grade II or III Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Cancer Type: Prostate Cancer

Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type: Head and Neck Cancer

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Cancer Type: Bile Duct Cancer, Liver Cancer / Hepatoblastoma, Solid Tumor, Unknown Primary

Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Cancer Type: Brain & Spinal Cord Tumor

Registry Study for Radiation Therapy Outcomes
Cancer Type: Solid Tumor

REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type: Sarcoma

Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type: Multiple Myeloma, Plasma cell neoplasm

Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Cancer Type: Breast Cancer

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Siltuximab and Spartalizumab in Treating Participants with Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type: Sarcoma, Solid Tumor

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Cancer Type: Lung Cancer, Melanoma

Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5-15 Brain Metastases
Cancer Type: Brain & Spinal Cord Tumor, Unknown Primary

Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer
Cancer Type: Lung Cancer

Study of ASN004 in Patients With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type: Leukemia

Study of INBRX-105 in Patients With Solid Tumors
Cancer Type: Lung Cancer, Melanoma

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type: Lung Cancer, Melanoma, Stomach/ Gastric Cancer

Study of INCA 0186 in Subjects With Advanced Solid Tumors
Cancer Type: Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Stomach/ Gastric Cancer

Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Cancer Type: Breast Cancer, Colon/Rectal Cancer, Melanoma

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Cancer Type: Leukemia, Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type: Unknown Primary

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type: Hematopoietic Malignancies, Multiple Myeloma, Non-Hodgkin Lymphoma

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer, Unknown Primary

Study to Evaluate the Safety and Efficacy of Magrolimab Combination Therapy in Adults With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy
Cancer Type: Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Cancer Type: Hematopoietic Malignancies, Solid Tumor

Talazoparib, Radiation Therapy, and Atezolizumab for the Treatment of gBRCA 1/2 Negative, PD-L1 Positive, Metastatic Triple-Negative Breast Cancer, TARA Study
Cancer Type: Breast Cancer

Talimogene laherparepvec before Surgery for the Treatment of High-Risk and Treatment-Naive Recurrent Melanoma
Cancer Type: Melanoma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Telotristat Ethyl in Promoting Weight Stability in Patients with Recurrent Advanced Pancreatic Adenocarcinoma
Cancer Type: Pancreatic Cancer, Unknown Primary

Testing Cabozantinib in Patients with Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Cancer Type: Neuroendocrine Tumor

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type: Lung Cancer

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
Cancer Type: Sarcoma, Unknown Primary

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Cancer Type: Uterine Cancer

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Cancer Type: Ovarian Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type: Neuroendocrine Tumor, Unknown Primary

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients with Stage I-III Early Stage Breast Cancer
Cancer Type: Breast Cancer

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Cancer Type: Leukemia, Lymphoma, Non-Hodgkin Lymphoma

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Ultrasound in Diagnosing Patients with Skin Lesions
Cancer Type: Unknown Primary

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Cancer Type: Breast Cancer

Vaccine Therapy in Preventing Recurrence in Patients with Her-2 Positive Stage I-III Breast Cancer
Cancer Type: Breast Cancer

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Cancer Type: Hematopoietic Malignancies, Plasma cell neoplasm, Unknown Primary

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type: Brain & Spinal Cord Tumor

Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Cancer Type: Colon/Rectal Cancer

Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type: Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

VX15/2503 with or without Ipilimumab and/or Nivolumab in Treating Patients with Resectable Stage IIIB-D Melanoma
Cancer Type: Melanoma, Unknown Primary
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.